Blackhawk Capital Partners LLC Makes New Investment in Medtronic PLC $MDT

Blackhawk Capital Partners LLC bought a new stake in Medtronic PLC (NYSE:MDT) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,300 shares of the medical technology company’s stock, valued at approximately $1,171,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. AXQ Capital LP increased its holdings in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares in the last quarter. GC Wealth Management RIA LLC grew its holdings in Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after buying an additional 5,734 shares in the last quarter. Merit Financial Group LLC raised its position in Medtronic by 37.5% in the 2nd quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock valued at $4,972,000 after buying an additional 15,561 shares during the last quarter. Verdence Capital Advisors LLC lifted its stake in Medtronic by 22.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after acquiring an additional 5,296 shares in the last quarter. Finally, World Investment Advisors boosted its holdings in Medtronic by 1.9% during the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock worth $13,608,000 after acquiring an additional 2,868 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MDT shares. Jefferies Financial Group reissued a “hold” rating and set a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. JPMorgan Chase & Co. lifted their target price on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Truist Financial reduced their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Barclays increased their price target on Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. Finally, Sanford C. Bernstein boosted their price objective on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Fourteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Price Performance

Medtronic stock opened at $100.98 on Friday. The business’s 50 day simple moving average is $99.44 and its 200 day simple moving average is $95.23. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a market cap of $129.45 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 2.67 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).